References
Otrock ZK, Azar ST, Shamseddeen WA, Habr D, Inati A, Koussa S et al (2006) Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol 85(9):605–609
Perifanis V, Vyzantiadis T, Tziomalos K, Vakalopoulou S, Garipidou V, Athanassiou-Metaxa M et al (2007) Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Ann Hematol 86(1):23–30
Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E (2008) Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica 93(10):1588–1590
Naithani R, Seth T, Tandon N, Chandra J, Pati H, Saxena R et al (2017) Fractures and low bone mineral density in patients with beta thalassemia major. Indian J Hematol Blood Transfus. doi:10.1007/s12288-017-0820-1
Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K (2006) Bisphosphonate induced hypocalcaemia: report of 3 cases and review of literature. Endocr Pract 12:48–53
Acknowledgement
Financial support was obtained from Shantha Biotech for DXA scans and zoledronic acid for these patients.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interests
All the authors declares that they have no conflict of interests.
Informed Consent
Informed consent was obtained from all individual participants included in the study. This was part of DM thesis.
Rights and permissions
About this article
Cite this article
Naithani, R., Seth, T., Tandon, N. et al. Safety of Zoledronic Acid in Patients with Thalassemia Associated Low Bone Mineral Density. Indian J Hematol Blood Transfus 34, 345–346 (2018). https://doi.org/10.1007/s12288-017-0858-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-017-0858-0